LLY

733.87

+2.71%↑

JNJ

149.53

+2.14%↑

UNH

273.23

-11.3%↓

ABBV

181.65

+2.56%↑

NVO

66.05

+2.69%↑

LLY

733.87

+2.71%↑

JNJ

149.53

+2.14%↑

UNH

273.23

-11.3%↓

ABBV

181.65

+2.56%↑

NVO

66.05

+2.69%↑

LLY

733.87

+2.71%↑

JNJ

149.53

+2.14%↑

UNH

273.23

-11.3%↓

ABBV

181.65

+2.56%↑

NVO

66.05

+2.69%↑

LLY

733.87

+2.71%↑

JNJ

149.53

+2.14%↑

UNH

273.23

-11.3%↓

ABBV

181.65

+2.56%↑

NVO

66.05

+2.69%↑

LLY

733.87

+2.71%↑

JNJ

149.53

+2.14%↑

UNH

273.23

-11.3%↓

ABBV

181.65

+2.56%↑

NVO

66.05

+2.69%↑

Search

Quidel Corp

Abrir

32.53 -5.66

Visão Geral

Variação de preço das ações

24h

Atual

Mín

32.06

Máximo

34.24

Indicadores-chave

By Trading Economics

Funcionários

6,600

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+23.91% upside

Dividendos

By Dow Jones

Próximos Ganhos

30 de jul. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

493M

2.2B

Abertura anterior

38.19

Fecho anterior

32.53

Quidel Corp Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

14 de mai. de 2025, 23:40 UTC

Ações em Alta

Stocks to Watch: UnitedHealth Group, Foot Locker, CoreWeave

14 de mai. de 2025, 23:33 UTC

Grandes Movimentos do Mercado

UnitedHealth Group Shares Fall After WSJ Reports of Investigation for Possible Medicare Fraud

14 de mai. de 2025, 23:25 UTC

Grandes Movimentos do Mercado

Biohaven Shares Down as FDA Extends PDUFA Data for Troriluzole

14 de mai. de 2025, 23:25 UTC

Ganhos

Xero Lifts Fiscal Year Profit 30% on Higher Prices, Subscriber Growth -- Update

14 de mai. de 2025, 22:58 UTC

Ganhos

Xero Lifts Fiscal Year Profit 30% on Higher Prices, Subscriber Growth

14 de mai. de 2025, 21:35 UTC

Ganhos

Cisco Systems Names Patterson as CFO, Patel as President

14 de mai. de 2025, 23:59 UTC

Conversa de Mercado

Implications of Xero's Cost Outlook Aren't Clear -- Market Talk

14 de mai. de 2025, 23:49 UTC

Conversa de Mercado

Xero's Cost Outlook Likely to Prompt Downgrades -- Market Talk

14 de mai. de 2025, 23:48 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

14 de mai. de 2025, 23:48 UTC

Conversa de Mercado

Nikkei May Decline on Profit-Taking After Recent Gains -- Market Talk

14 de mai. de 2025, 23:47 UTC

Conversa de Mercado

Gold Gains on Possible Technical Recovery -- Market Talk

14 de mai. de 2025, 23:34 UTC

Aquisições, Fusões, Aquisições de Empresas

Agnico-Eagle Mines to Subscribe for 30M Voting Common Shares of Foran Mining in Non-Brokered Private Placement at C$3 a Share

14 de mai. de 2025, 23:10 UTC

Ganhos

Xero Lifts FY Profit 30% on Higher Prices, Subscriber Growth -- Update

14 de mai. de 2025, 23:07 UTC

Ganhos

CoreWeave Posts Strong Revenue and Wins Google as a Customer. Stock Still Dives on Outlook. -- Barrons.com

14 de mai. de 2025, 23:00 UTC

Principais Notícias

UnitedHealth Group Is Under Criminal Investigation for Possible Medicare Fraud -- WSJ

14 de mai. de 2025, 22:43 UTC

Ganhos

Xero Lifts FY Profit 30% on Higher Prices, Subscriber Growth

14 de mai. de 2025, 22:34 UTC

Ganhos

Xero Expects 1H Operating Expense Ratio to Be Higher Than 2H>XRO.AU

14 de mai. de 2025, 22:33 UTC

Ganhos

Xero Expects FY26 Operating Expense Ratio of 71.5%>XRO.AU

14 de mai. de 2025, 22:30 UTC

Ganhos

Xero Did Not Declare a Dividend>XRO.AU

14 de mai. de 2025, 22:30 UTC

Ganhos

Xero FY Operating Expenses 71.8% of Operating Revenue Vs. 73.3%>XRO.AU

14 de mai. de 2025, 22:30 UTC

Ganhos

Xero FY Free Cashflow Margin 24.1% Vs. 20.0%>XRO.AU

14 de mai. de 2025, 22:30 UTC

Ganhos

Xero FY Free Cashflow NZD506.7M Vs. NZD342.1M>XRO.AU

14 de mai. de 2025, 22:28 UTC

Ganhos

Xero FY Ebitda NZD638.5M Vs. NZD497.4M>XRO.AU

14 de mai. de 2025, 22:28 UTC

Ganhos

Xero FY Adjusted Ebitda NZD640.6M Vs. NZD526.5M>XRO.AU

14 de mai. de 2025, 22:27 UTC

Ganhos

Xero FY Rev NZD2.10B Vs. NZD1.71B >XRO.AU

14 de mai. de 2025, 22:27 UTC

Ganhos

Xero FY Net NZD227.8M Vs. Net NZD174.6M >XRO.AU

14 de mai. de 2025, 22:23 UTC

Principais Notícias

Boeing, GE Aerospace Get Qatar Airways Order After Saudi AI Tech Deals -- 2nd Update

14 de mai. de 2025, 22:15 UTC

Ganhos

Correction to Cisco Earnings Article -- WSJ

14 de mai. de 2025, 21:48 UTC

Ganhos

CoreWeave Posts Strong Revenue but Stock Dives on Updated Outlook -- Barrons.com

14 de mai. de 2025, 21:37 UTC

Ganhos

Cisco Reports Solid Earnings. The Stock Is Rising. -- Barrons.com

Comparação entre Pares

Variação de preço

Quidel Corp Previsão

Preço-alvo

By TipRanks

23.91% parte superior

Previsão para 12 meses

Média 44 USD  23.91%

Máximo 60 USD

Mínimo 27 USD

Com base em 6 analistas de Wall Street que oferecem metas de preço de 12 meses para Quidel Corp - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

6 ratings

3

Comprar

2

Manter

1

Vender

Informação Financeira

$

Sobre Quidel Corp

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides instruments and tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was incorporated in 1979 and is headquartered in San Diego, California.